Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07146893 · ClinicalTrials.gov registry record · Early Phase 1
Feasibility Study for Repurposing RET Inhibitors
A Early Phase 1 study, sponsored by University of Oklahoma.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT07146893: Clinical Trial Early Phase 1 study, sponsored by University of Oklahoma.
NCT07146893 is a Early Phase 1 study that has not yet begun recruiting, run by University of Oklahoma. The registered enrollment target is 7 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07146893, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of Oklahoma.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects of selpercatinib on cachexia and anorexia in patients diagnosed with NSCLC, colorectal cancer, or pancreatic cancer.
Primary Outcome
At screening, patients will have their initial weight recorded. While on study, they will take selpercatinib orally twice daily, with weight assessments conducted every four weeks (Weeks 4, 8, and 12). Selpercatinib will be discontinued at Week 12, and at the 16-week post-treatment follow-up, patients will return to the clinic for a final weight assessment.
Interventions
- DRUG Selpercatinib
- OTHER Strength Assessment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2026-02-26 |
| Est. Completion | 2028-02-23 |
| Phase | Early Phase 1 |
What is known before NCT07146893 opens enrollment
NCT07146893 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Selpercatinib is the first listed.
NCT07146893 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07146893 about?
NCT07146893 is a clinical study titled "Feasibility Study for Repurposing RET Inhibitors". The purpose of this study is to assess the effects of selpercatinib on cachexia and anorexia in patients diagnosed with NSCLC, colorectal cancer, or pancreatic cancer.
What is the current status of trial NCT07146893?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2026-02-26. Estimated completion is 2028-02-23.
What interventions are being tested in trial NCT07146893?
The interventions under investigation include: Selpercatinib (DRUG), Strength Assessment (OTHER).
Who is sponsoring clinical trial NCT07146893?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07146893's enrollment target sits among peer trials
7 1825th of 2000 higher than 156 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI